Management Option 1: Recommend Upfront Consolidation with High dose Melphalan and Autologous Stem Cell Support

56 year old man with ISS Stage II multiple myeloma and 70% plasma cell infiltration in the bone marrow and normal cytogenetics returns after completing 6 cycles of induction therapy. On laboratory evaluation, the patient has no monoclonal protein on serum and urine electrophoresis and immunofixation and the free light chain ratio is within normal limits. A bone marrow biopsy reveals normal trilineage hematopoiesis with less than 5% plasma cells. Multicolor flow cytometric analysis of the bone marrow aspirate reveals minimal residual disease (MRD) (sensitivity 1 in 105).
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Source Type: research